Jennifer Lachey Sells 2,650 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Jennifer Lachey sold 2,650 shares of the company’s stock in a transaction on Tuesday, January 11th. The stock was sold at an average price of $53.75, for a total transaction of $142,437.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jennifer Lachey also recently made the following trade(s):

  • On Wednesday, January 5th, Jennifer Lachey sold 2,650 shares of Keros Therapeutics stock. The stock was sold at an average price of $60.00, for a total transaction of $159,000.00.
  • On Monday, December 13th, Jennifer Lachey sold 1,915 shares of Keros Therapeutics stock. The shares were sold at an average price of $50.55, for a total transaction of $96,803.25.
  • On Wednesday, December 15th, Jennifer Lachey sold 735 shares of Keros Therapeutics stock. The shares were sold at an average price of $50.00, for a total transaction of $36,750.00.
  • On Wednesday, November 10th, Jennifer Lachey sold 15,900 shares of Keros Therapeutics stock. The shares were sold at an average price of $60.00, for a total transaction of $954,000.00.

KROS opened at $51.78 on Friday. The firm has a market cap of $1.21 billion, a P/E ratio of -19.11 and a beta of 1.13. The firm has a 50-day moving average of $55.93 and a 200 day moving average of $43.78. Keros Therapeutics, Inc. has a fifty-two week low of $28.50 and a fifty-two week high of $75.99.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Thursday, November 4th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.15). Equities analysts predict that Keros Therapeutics, Inc. will post -3.14 EPS for the current year.

Separately, Zacks Investment Research downgraded shares of Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 5th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $76.25.

A number of institutional investors and hedge funds have recently bought and sold shares of KROS. New York State Common Retirement Fund grew its position in Keros Therapeutics by 20.2% during the second quarter. New York State Common Retirement Fund now owns 14,302 shares of the company’s stock valued at $607,000 after buying an additional 2,402 shares during the period. Swiss National Bank grew its position in Keros Therapeutics by 36.4% during the second quarter. Swiss National Bank now owns 28,100 shares of the company’s stock valued at $1,193,000 after buying an additional 7,500 shares during the period. State Board of Administration of Florida Retirement System boosted its position in Keros Therapeutics by 52.6% during the second quarter. State Board of Administration of Florida Retirement System now owns 6,410 shares of the company’s stock worth $272,000 after purchasing an additional 2,210 shares during the period. Virtus ETF Advisers LLC boosted its position in Keros Therapeutics by 10.3% during the second quarter. Virtus ETF Advisers LLC now owns 4,229 shares of the company’s stock worth $180,000 after purchasing an additional 394 shares during the period. Finally, Psagot Investment House Ltd. bought a new position in Keros Therapeutics during the second quarter worth about $2,420,000. Institutional investors own 58.74% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Recommended Story: What are the reasons investors use put options?

Insider Buying and Selling by Quarter for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.